Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 PK and QT/QTc Study in Healthy Subjects
NCT07378579Phase 1Completed
- Sponsor
- Alumis Inc.
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of envudeucitinib in plaque psoriasis and systemic lupus erythematosus (SLE), sponsored by Alumis Inc. Primary endpoint: Change from baseline in placebo-adjusted QTcF at 24 hours. Started Jun 2024; status: completed.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasissystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07378579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07378579.